IRTPA: Integrated Rehabilitation in Treating Post-stroke Anxiety

Sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05147077
Collaborator
(none)
188
1
2
35.2
5.3

Study Details

Study Description

Brief Summary

Post-stroke anxiety (PSA) is a common complication of stroke that leads to dysfunction and reduces the quality of life. PSA exacerbates cognitive dysfunction, delays the recovery process, and increases the disability, mortality, and recurrence rates of stroke. Therefore, early clinical treatments for PSA are important to improve the prognosis and restore the social functions of stroke patients.

Integrated rehabilitation has significant advantages in the treatment of PSA. First of all, there is a wide range of rehabilitation methods, such as acupuncture, traditional Chinese medicine, and repetitive transcranial magnetic stimulation, which have been proved to be effective for PSA. However, as the application of integrated rehabilitation becomes more and more widespread, its shortcomings are gradually emerging. For example, most of the treatment protocols used in clinical studies are based on personal experience of the investigators, a unified protocol has not yet been formed, treatment methods are still insufficient in standardization and reproducibility. More studies focus solely on the improvement of a certain symptom by a certain rehabilitation therapy, but ignore the important theoretical basis of the "holistic concept", thus showing the uneven clinical efficacy. For the above existing problems, it is necessary to conduct original and innovative research.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Acupuncture
N/A

Detailed Description

This randomized controlled trial will enroll 188 PSA patients from the Third Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang General Hospital of Armed Police, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, and Jinhua Second Hospital. All patients will be randomly assigned to either the integrated rehabilitation group or the standard care group through a randomization system. The primary outcome will be assessed by hamilton anxiety (HAMA) scale, self-rating anxiety scale (SAS), and activity of daily living (ADL) scale. Secondary outcomes will include montreal cognitive assessment (MoCA) scale, the simple fugl-meyer assessment of motor function (FMA) scale and pittsburgh sleep quality index (PSQI).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
188 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Integrated Rehabilitation in Treating Post-stroke Anxiety: Study Protocol for a Multicentre, Prospective, Randomised, Controlled Trial
Actual Study Start Date :
Jan 24, 2022
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Integrated rehabilitation group

This group will include 94 patients. On the basis of standard care, patients in this group will receive acupuncture, traditional Chinese medicine, repetitive transcranial magnetic stimulation.

Procedure: Acupuncture
Acupuncture: Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees. Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2). Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g. Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz. Standard care The same as the standard care group.
Other Names:
  • Traditional Chinese medicine
  • Repetitive transcranial magnetic stimulation
  • Standard care
  • Active Comparator: Standard care group

    The patients were recommended to take one oral tablet of escitalopram oxalate (10 mg) every morning after a meal for 4 weeks. Internal medicine includes lipid regulation, blood sugar control, anti-hypertension, anticoagulation, and other drugs. Moreover, general duty nursing and motor therapy are also needed.

    Procedure: Acupuncture
    Acupuncture: Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees. Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2). Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g. Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz. Standard care The same as the standard care group.
    Other Names:
  • Traditional Chinese medicine
  • Repetitive transcranial magnetic stimulation
  • Standard care
  • Outcome Measures

    Primary Outcome Measures

    1. Change in hamilton anxiety (HAMA) scale [Baseline, at 4-week during treatment, at 8-week follow-up]

      The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety).

    2. Change in self-rating anxiety scale (SAS) [Baseline, at 4-week during treatment]

      The Zung Self-Rating Anxiety Scale (SAS) is a method of measuring levels of anxiety in patients who have anxiety-related symptoms. The scale focuses on the most common general anxiety disorders; coping with stress typically causes anxiety. The SAS test is self-administered, with each response using a 4-point scale, from 'none of the time" to "most of the time." There are 20 questions with 15 increasing anxiety level questions and 5 decreasing anxiety questions. There are two formats, self-evaluations and clinical evaluations.

    3. Change in activity of daily living (ADL) scale [Baseline, at 4-week during treatment, at 8-week follow-up]

      The Activities of Daily Living are a series of basic activities necessary for independent living at home or in the community. They are performed on a daily basis. There are many variations on the definition of the ADLs, but most organizations agree there are 5 basic categories.

    Secondary Outcome Measures

    1. Change in Montreal cognitive assessment (MoCA) scale [Baseline, at 4-week during treatment]

      Montreal Cognitive Assessment scoring is based on a 30-point scale, with points awarded differently depending on the type of question asked. For instance, you can earn one point for each animal you identify in a picture, but listing the names of 13 fruits in under a minute gains you only two points.

    2. Change in the Fugl-meyer assessment of motor function (FMA) scale [Baseline, at 4-week during treatment]

      Scoring is based on direct observation of performance. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226. Points are divided among the domains as follows: Motor score: ranges from 0 (hemiplegia) to 100 points (normal motor performance). Divided into 66 points for upper extremity and 34 points for the lower extremity. Sensation: ranges from 0 to 24 points. Divided into 8 points for light touch and 16 points for position sense. Balance: ranges from 0 to 14 points. Divided into 6 points for sitting and 8 points for standing. Joint range of motion: ranges from 0 to 44 points. Joint pain: ranges from 0 to 44 points.

    3. Change in Pittsburgh sleep quality index (PSQI) [Baseline, at 4-week during treatment, at 8-week follow-up]

      The range of values for questions 5 through 10 are all 0 to 3. Questions 1 through 9 are not allowed to be missing except as noted below. If these questions are missing then any scores calculated using missing questions are also missing. Thus it is important to make sure that all questions 1 through 9 have been answered. In the event that a range is given for an answer (for example, '30 to 60' is written as the answer to Q2, minutes to fall asleep), split the difference and enter 45.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Meet the diagnostic criteria of cerebral infarction or cerebral hemorrhage with anxiety disorder, the type of depression and clinical syndrome of liver stagnation transforming into fire;

    • Patients with clear consciousness, stable vital signs, ability to understand and cooperate with instructions, barthel index (BI) > 20, FMA (0-95), Mini-mental State Examination (MMSE) meet the following criteria: illiterate > 17, primary school level

    20, secondary school level (including technical secondary school) > 22, and college level (including junior college) > 23 points;

    • 25 <= age <= 85 years, male or female;

    • First episode of stroke, no personal or family history of mental disability before the stroke;

    • Anxiety level as mild or moderate (HAMA scores >= 7 and <= 21);

    • Anxiety symptoms occur after the stroke in a clear temporal sequence;

    • The course of the PSA is limited to 2 weeks to 36 months after the stroke;

    • Participants can understand the study protocol and written informed consent is signed.

    Exclusion Criteria:
    • Patients with acute brain trauma, brain infection, effusion, or tumor occupation;

    • There are intracranial metals and other foreign bodies (such as orthopedic materials, arterial clips, etc.), cardiac pacemakers, deep brain stimulators and other electronic devices;

    • Previous seizures, including primary and secondary seizures;

    • Patients have severe complications in cardiovascular, liver, kidney or psychiatric history;

    • There is a significant cognitive impairment (MMSE: literacy <= 17, primary school level <= 20, secondary school level (including technical secondary school) <= 22, and college level (including junior college) <= 23 points) or hearing impairment, aphasia;

    • Coma, dying or chronic illness;

    • Patients have taken psychotropic drugs or been treated for anxiety for nearly a month;

    • People with unstable vital signs or patients with other mental disorders.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 the Third Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou Zhejiang China 310000

    Sponsors and Collaborators

    • The Third Affiliated hospital of Zhejiang Chinese Medical University

    Investigators

    • Principal Investigator: Hong Gao, Deputy dean, Third Affiliated Hospital of Zhejiang Chinese Medical University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hong Gao, Deputy dean, The Third Affiliated hospital of Zhejiang Chinese Medical University
    ClinicalTrials.gov Identifier:
    NCT05147077
    Other Study ID Numbers:
    • 2021ZX010-A
    First Posted:
    Dec 7, 2021
    Last Update Posted:
    Jun 27, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Hong Gao, Deputy dean, The Third Affiliated hospital of Zhejiang Chinese Medical University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 27, 2022